Alexion Pharmaceuticals, Inc. reveals it has concluded a large-scale product supply agreement with Lonza Biologics for the long term commercial manufacture of its C5 complement inhibitor antibody, eculizumab.
Alexion recently announced promising clinical results from clinical studies evaluating eculizumab treatment in membranous nephritis patients and patients with paroxysmal nocturnal hemoglobinuria. Additionally, a Phase IIb clinical study is currently ongoing with eculizumab in rheumatoid arthritis patients.
Commenting on the deal to supply eculizamab from Lonza Biologics’ new large scale facility in Portsmouth, NH, Markus Gemuend, CEO of Lonza Group acknowledged his company had been "fortunate to have worked with Alexion on eculizumab from its early development to current clinical trial supply."
Specific terms of the agreement have not been disclosed.
David Keiser, President and Chief Operating Officer of Alexion saw: "it was important to secure the manufacturing experience, expertise, state of the art facilities and capacity that Lonza is uniquely positioned to provide."
Keywords : Alexion Pharmaceuticals Lonza Biologics Contract biomanufacturing Supply agreement Eculizumab Nephritis Rheumatoid arthritis
